Recursion founder to leave board
- Recursion said co-founder Chris Gibson will leave its board on June 15, ending the handoff that made Najat Khan chief executive on January 1. (ir.recursion.com) - Gibson had already moved from CEO to board chair in November’s transition plan, and Recursion now says he will stay on only as advisor. (ir.recursion.com) - The move finishes a rare two-step founder exit — separating strategy support from formal board power as Recursion tries to prove its AI drug model. (ir.recursion.com)
Recursion is finishing a founder handoff that started last fall. The company said co-founder Chris Gibson will step down from its board on June 15, 2026, (ir.recursion.com)ontrol — who still runs the place, who still votes, who still shapes strategy. Recursion is trying to make the answer unusually clear: Khan runs the company, and Gibson stays involved only as an advisor. (ir.recursion.com) ### What changed now? The new piece is the board exit. Recursion said on May 1 that Gibson will resign from the(ir.recursion.com)he company going forward. That turns a staged succession into a cleaner governance structure — no founder in the CEO seat, and soon no founder in the board chair either. (ir.recursion.com) ### Didn’t Gibson already step back? Yes — but only partway. In November 2025, Recursion laid out a plan for Khan to become CEO and president on January 1, 2026, while Gibson moved from CEO to cha(ir.recursion.com)under from formal board authority too. (ir.recursion.com) ### Who is Najat Khan? Khan came into the role with a bigger remit than a standard internal promotion. Recursion had described her as chief R&D and commercial officer and already a board member before the CEO change(ir.recursion.com) company. In plain English, Recursion was not swapping in a caretaker — it was elevating someone already positioned across science, business, and corporate governance. (ir.recursion.com) ### Why does leaving the board matter so(ir.recursion.com)n, and investor signaling. Sometimes that continuity is stabilizing. But the catch is that it can also blur accountability. Recursion’s move makes the chain of command easier to read — Khan leads, the board oversees, Gibson advises. That is cleaner for employees, partners, and investors trying to figure out who owns the next chapter. (ir.recursion.com) ### Is Gibson disappearing from the company? No(ir.recursion.com)eady being formalized as part of the transition. So this is less a rupture than a narrowing of role. Gibson still helps, but without the same formal governance leverage that comes with a board seat. (ir.recursion.com) ### Why do this in two steps? Basically, it lowers execution risk. Recursion is still trying to prove that its AI-heavy drug discovery platform can translate into durable pipeline and clinical value. Duri(ir.recursion.com)ets the founder support the incoming CEO for a few months, then get out of the way. Recursion had also highlighted a cash runway through the end of 2027, which means the market will be watching execution more than emergency financing. (ir.recursion.com) ### What should (ir.recursion.com)nd less like a founder-led science project. That does not guarantee better performance. But it does remove one common source of confusion in biotech transitions — whether the new CEO is really in charge or just borrowing the seat. Here, the company is signaling that the baton pass is real. (ir.recursion.com) ### Bottom line? Recursion did not just replace a CEO. It finished the harder part — untangling founder influence from formal control while keeping (ir.recursion.com)pitch too. (ir.recursion.com)
